{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-082719","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-07-10T21:13:07+00:00","discovered_at":"2026-07-10T21:14:00.331321+00:00","generated_at":"2026-07-10T21:14:07.744631+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cellectar shareholders approve warrant exercise for up to 39.6M shares, increase share reserve by 2M","bullets":["Class III directors Andrew Gu and Douglas J. Swirsky elected to three-year terms.","Shareholders approved 2,000,000 share increase under 2021 Stock Incentive Plan.","Shareholders approved exercise of warrants for up to 39,618,078 shares of common stock.","Deloitte & Touche ratified as independent auditor for fiscal year 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-082719","json":"https://secwatch.observer/filing/0001104659-26-082719.json","markdown":"https://secwatch.observer/filing/0001104659-26-082719.md","text":"https://secwatch.observer/filing/0001104659-26-082719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/0001104659-26-082719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/tm2620219d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-10T21:14:07.744631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}